Other clinical trials also provided the evidence that mTOR inhibitors use in combination of low‐dose CsA or as alternative of CsA providing the incidence of skin cancer.22, 23 From the perspectives above, mTOR inhibitor provided a protective role in lessening the post‐transplantation malignancy. This evidence concerns the gene MTOR and skin neoplasm.